L-Cin OZ Tablet is a combination antibiotic formulation containing Levofloxacin 250 mg and Ornidazole 500 mg, designed for the treatment of mixed bacterial and protozoal infections. Levofloxacin, a fluoroquinolone antibiotic, exhibits broad-spectrum bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication and cell division. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing strand breakage. This synergistic combination is particularly useful in managing infections involving both aerobic and anaerobic pathogens, such as intra-abdominal infections, pelvic inflammatory disease, gastrointestinal infections, and certain respiratory tract infections. L-Cin OZ Tablet is indicated where polymicrobial infections are suspected or confirmed, providing comprehensive antimicrobial coverage. The medication should be administered as prescribed, with consideration of patient-specific factors including renal function and potential drug interactions. Adverse effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and use during pregnancy and lactation should be under strict medical supervision. Appropriate microbiological diagnosis and susceptibility testing are recommended to ensure optimal therapeutic outcomes.